Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Qui est le CEO de Ginkgo Bioworks Holdings Inc ?
Dr. Jason Kelly est le Chief Executive Officer de Ginkgo Bioworks Holdings Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action DNA ?
Le prix actuel de DNA est de $11.54, il a decreased de 0.4% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Ginkgo Bioworks Holdings Inc ?
Ginkgo Bioworks Holdings Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Ginkgo Bioworks Holdings Inc ?
La capitalisation boursière actuelle de Ginkgo Bioworks Holdings Inc est de $648.7M
Est-ce que Ginkgo Bioworks Holdings Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Ginkgo Bioworks Holdings Inc, y compris 0 achat fort, 1 achat, 2 maintien, 5 vente et 0 vente forte
